Scott Hastings, DO
Adult Medicine · Frisco, TXNPI 1174597553
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 56 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $370 and has fallen 56.5% since, to $161 in 2025.
Across 56 payments — averaging $19.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$159
- Si-bone, Inc.$61
- Lilly USA, LLC$53
- Boehringer Ingelheim$52
- Otsuka America Pharmaceutical, Inc.$51
- Amgen$46
- plus $694 from 29 others
What the payments were for
- Food & beverage$1,117100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 8 | $159 |
| Si-bone, Inc. | 2 | $61 |
| Lilly USA, LLC | 4 | $53 |
| Boehringer Ingelheim | 2 | $52 |
| Otsuka America Pharmaceutical, Inc. | 2 | $51 |
| Amgen(2 entities) | 2 | $46 |
| Medtronic | 2 | $44 |
| AbbVie | 2 | $41 |
| Inspire Medical Systems, Inc. | 1 | $41 |
| Idorsia Pharmaceuticals US Inc | 2 | $39 |
| Exact Sciences | 2 | $35 |
| Bayer | 2 | $33 |
| Abbott | 2 | $31 |
| Supernus Pharmaceuticals, Inc. | 2 | $31 |
| Ironshore Pharmaceuticals Inc. | 1 | $27 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Photonicare Inc | 1 | $25 |
| Alk-abello, Inc | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Linus Health, Inc. | 1 | $21 |
| Tempus AI, Inc | 1 | $19 |
| AstraZeneca | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Merck | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Antares Pharma, Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| Nevro Corp. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Acella Pharmaceuticals, LLC | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| GSK | 1 | $15 |
| Viiv Healthcare Company | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
How this compares
$1,117 in reported general payments places this provider in the 60th percentile of 98 adult medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 29 | $40,605 |
| OzempicSemaglutide | 34 | $38,037 |
| JardianceEmpagliflozin | 16 | $22,708 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $6,999 |
| Liothyronine Sodium | 41 | $1,938 |
| Levothyroxine Sodium | 215 | $1,547 |
| Atorvastatin Calcium | 247 | $1,535 |
| Gabapentin | 85 | $1,374 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 45 | $1,278 |
| Estradiol | 33 | $1,098 |
| Metformin Hcl ErMetformin Hcl | 100 | $1,052 |
| Losartan Potassium | 126 | $1,025 |
| Glipizide ErGlipizide | 57 | $973 |
| Celecoxib | 23 | $842 |
| Amlodipine Besylate | 133 | $807 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $159 | $40,60529 claims |
| Boehringer IngelheimJardiance | $52 | $22,70816 claims |
| GSKTrelegy Ellipta | $15 | $6,99911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 98 adult medicine providers in Texas.
Other adult medicine in Frisco
- Kiran MendhaFrisco$1K
- Deborah HornBellaire$723K
- Thomas MartensPflugerville$87K
- Sakuntalai SrinanthakumarBeaumont$48K
- Francisco Vera AdamesSpring$11K
- Latisha RoweHouston$11K
- Hong XiaoCarrollton$10K
- Mark NovasSheppard Afb$9K
- Daisy ArceWeslaco$9K
- Jeffory ThomasTexarkana$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.